Vincerx Pharma, Inc.

Vincerx Pharma, Inc. (Nasdaq: VINC) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for hematologic malignancies and solid tumors. The company became publicly traded in January 2021 through a business combination with LifeSci Acquisition Corp, a blank-check vehicle sponsored by LifeSci Acquisition LLC that completed its initial public offering in 2020. On May 28, 2024, Vincerx filed an 8-K current report with the SEC under accession number 0001193125-24-148090, disclosing a material event in the ordinary course of its post-merger public-company operations within the oncology and hematology sector. For complete filing histories, SPAC deal timelines, and real-time post-merger alerts on Vincerx and hundreds of other transactions, sign up for full data access at SpacDesk.